It has been reported that the NLRP3 inflammasome is activated in the synovium of RA mice, and that treatment with a selective NLRP3 inhibitor can reduce the symptoms of arthritis and cartilage destruction [7–9]. This evidence concerns the gene NLRP3 and arthritic joint disease.